专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2606340A2 PORTABLE SYSTEM FOR ANALYZING AND DETERMINING ELEMENTAL COMPOSITION OF ROCK SAMPLES 审中-公开
标题翻译：便携式系统的调查和确定岩石样品的元素组成
公开(公告)号：EP2606340A2
公开(公告)日：2013-06-26
申请号：EP11817831.8
申请日：2011-08-19
申请人： Faber, Daniel , Oda, Susan , Bell, Adam , Ducellier, Thomas
发明人： Faber, Daniel , Oda, Susan , Bell, Adam , Ducellier, Thomas
IPC分类号： G01N23/05 , G21C17/10
CPC分类号： G01T1/1611 , G01N23/222 , G01N2223/0745
摘要： A portable system for elemental analysis includes one or more neutron emitters, a chamber for containing a test sample, at least one gamma ray detector electrically connected to a data acquisition system, and software or firmware executing on the data acquisition system from a non-transitory physical medium, the software or firmware providing a first function for producing one or more gamma ray spectrums, a second function for applying correction factors to the one or more gamma ray spectrums, and a third function for analyzing the corrected gamma ray spectrum or spectrums to determine a deconvolved elemental composition of the test sample.

2. 发明申请

WO2007146038A3 ALBUMIN FUSION PROTEINS 审中-公开
公开(公告)号：WO2007146038A3
公开(公告)日：2008-10-09
申请号：PCT/US2007013383
申请日：2007-06-07
申请人： HUMAN GENOME SCIENCES INC , ROSEN CRAIG A , BELL ADAM , LAFLEUR DAVID W , WOODS DOUGLAS B , FENG PING , SMITH RODGER G
发明人： ROSEN CRAIG A , BELL ADAM , LAFLEUR DAVID W , WOODS DOUGLAS B , FENG PING , SMITH RODGER G
IPC分类号： A61K38/26 , C07K14/605 , C07K14/76
CPC分类号： C12N9/96 , A61K38/00 , C07K14/765 , C07K2319/00 , C12N15/62
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

3. 发明申请

WO2008052043A2 OPIOID RECEPTOR AGONIST FUSION PROTEINS 审中-公开
标题翻译：阿片受体激动剂融合蛋白
公开(公告)号：WO2008052043A2
公开(公告)日：2008-05-02
申请号：PCT/US2007/082363
申请日：2007-10-24
申请人： COGENESYS, INC. , ROSEN, Craig, A. , BELL, Adam, C. , SANYAL, Indrajit , LAFLEUR, David
发明人： ROSEN, Craig, A. , BELL, Adam, C. , SANYAL, Indrajit , LAFLEUR, David
IPC分类号： C07K14/435
CPC分类号： C07K14/665 , C07K14/4715 , C07K2319/00
摘要： Disclosed are fusion proteins that include an opioid receptor agonist protein, or a fragment, variant, or an analog thereof fused to a serum protein. Suitable serum proteins for the fusion proteins in albumin, alpha- fetoprotein (AFP) and albumin- AFP hybrid proteins. The fusion proteins have opioid receptor agonist activity. Typically, the fusion proteins may exhibit extended or stabilized opioid receptor agonist activity in vivo or in vitro relative to an opioid receptor agonist that is not fused to the serum protein.
摘要翻译：公开了融合蛋白，其包含与血清蛋白融合的阿片受体激动剂蛋白或其片段，变体或类似物。用于白蛋白，甲胎蛋白（AFP）和白蛋白AFP杂交蛋白中的融合蛋白的合适的血清蛋白。融合蛋白具有阿片受体激动剂活性。通常，融合蛋白可以相对于不与血清蛋白融合的阿片样物质受体激动剂在体内或体外表现出延长的或稳定的阿片受体激动剂活性。

4. 发明申请

WO2008019368A2 ALBUMIN-INSULIN FUSION PROTEINS 审中-公开
标题翻译：蛋白 - 胰岛素融合蛋白
公开(公告)号：WO2008019368A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/075361
申请日：2007-08-07
申请人： COGENESYS, INC. , BELL, Adam, C. , ROSEN, Craig, A. , SANYAL, Indrajit , ZHAO, Qinghai
发明人： BELL, Adam, C. , ROSEN, Craig, A. , SANYAL, Indrajit , ZHAO, Qinghai
IPC分类号： C07K14/62 , C07K14/765 , A61K38/28 , A61K38/38 , A61P3/10 , C12N15/17 , C12N5/10
CPC分类号： C07K14/62 , A61K38/28 , C07K14/765 , C07K2319/35 , C12N15/62
摘要： Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.
摘要翻译：公开了包含与具有胰岛素活性的多肽融合的白蛋白的融合蛋白。融合蛋白可以包括与胰岛素融合的白蛋白或胰岛素类似物。特别地，融合蛋白可以包括与单链胰岛素类似物融合的白蛋白。相对于未与白蛋白融合的胰岛素，融合蛋白可在体内或体外表现出延长的胰岛素活性。融合蛋白可以配制成气溶胶组合物。

5. 发明申请

WO2009073192A3 SYSTEMS AND METHODS FOR DELIVERY OF MATERIALS 审中-公开
标题翻译：用于输送材料的系统和方法
公开(公告)号：WO2009073192A3
公开(公告)日：2009-10-22
申请号：PCT/US2008013335
申请日：2008-12-03
申请人： LANDEC CORP , TAFT DAVID D , BITLER STEVEN P , ZHENG QIANG , TZANNIS STELIOS T , BELL ADAM W , DAI WEI-GUO , OTTENSMANN SANDRA N , BALACHANDER NATARAJAN
发明人： TAFT DAVID D , BITLER STEVEN P , ZHENG QIANG , TZANNIS STELIOS T , BELL ADAM W , DAI WEI-GUO , OTTENSMANN SANDRA N , BALACHANDER NATARAJAN
IPC分类号： A61K9/16 , A61K31/196 , A61K31/519 , A61P25/18 , A61P29/00
CPC分类号： A61K9/146 , A61K9/1647 , A61K31/136 , A61K31/196 , A61K31/519 , A61K31/5513 , A61K47/34
摘要： Systems and methods for delivering release materials, for example drugs and other bioactive materials. Crystalline polymeric systems, referred to as CYC carriers, are associated with the release materials, through chemical bonding or through physical association. The crystallinity of the CYC carriers results from the presence of crystallizable side chains, for example long chain n-alkyl moieties, which results in relatively low and sharp melting temperatures. One class of CYC carriers, referred to as CYSC polymers, have a majority of the crystallizable side chains pendant from the polymer backbone. Another class of CYC carriers, referred to as ECC polymers, have a majority of the crystallizable side chains attached to terminal units of the polymer backbone. The ECC polymers can for example be obtained by modification of PLGA polymers. The CYC carriers in another class of non-polymeric. Some CYC carriers, referred to as CYC assemblies, have enhanced crystallinity as a result of the physical association of crystallizable moieties which are present in different types of molecule, for example between a polymer containing crystallizable moieties and a monomer containing crystallizable moieties. For some uses, particularly the delivery of drugs, a bioerodable CYC carrier is preferably used.
摘要翻译：用于输送释放材料的系统和方法，例如药物和其他生物活性材料。称为CYC载体的结晶聚合体系通过化学键合或通过物理缔合与释放材料相关联。 CYC载体的结晶度来自可结晶侧链的存在，例如长链正烷基部分，这导致相对低的和尖锐的熔融温度。称为CYSC聚合物的一类CYC载体具有从聚合物主链悬挂的大部分可结晶侧链。称为ECC聚合物的另一类CYC载体具有连接至聚合物主链末端单元的大部分可结晶侧链。 ECC聚合物可以例如通过改性PLGA聚合物获得。 CYC载体在另一类非聚合物中。一些称为CYC组件的CYC载体由于存在于不同类型分子中的可结晶部分的物理结合而具有增强的结晶度，例如在含可结晶部分的聚合物和含可结晶部分的单体之间。对于一些用途，特别是药物的递送，优选使用生物侵蚀性CYC载体。

6. 发明申请

WO2008070165A1 DRUG-CONTAINING COMPOSITIONS AND THEIR USE 审中-公开
标题翻译：含药组合物及其使用
公开(公告)号：WO2008070165A1
公开(公告)日：2008-06-12
申请号：PCT/US2007/025032
申请日：2007-12-05
申请人： LANDEC CORPORATION , TAFT, David, D. , BITLER, Steven, P. , ZHENG, Qiang , TZANNIS, Stelios, T. , BELL, Adam, Warwick
发明人： TAFT, David, D. , BITLER, Steven, P. , ZHENG, Qiang , TZANNIS, Stelios, T. , BELL, Adam, Warwick
IPC分类号： A61K47/30 , A61K47/32 , A61K9/10 , A61K9/20 , A61K9/32
CPC分类号： A61K9/0024 , A61K9/0019 , A61K9/146
摘要： Formulations of drugs and crystalline side chain polymers to provide controlled and/or sustained release drug formulations.
摘要翻译：制备药物和结晶侧链聚合物以提供受控和/或缓释药物制剂。

7. 发明申请

WO2005077042A3 ALBUMIN FUSION PROTEINS 审中-公开
标题翻译： ALBUMIN融合蛋白
公开(公告)号：WO2005077042A3
公开(公告)日：2006-11-30
申请号：PCT/US2005004041
申请日：2005-02-09
申请人： HUMAN GENOME SCIENCES INC , ROSEN CRAIG A , HASELTINE WILLIAM A , MOORE PAUL A , BOCK JASON B , BELL ADAM , SHI YANGGU , LAFLEUR DAVID
发明人： ROSEN CRAIG A , HASELTINE WILLIAM A , MOORE PAUL A , BOCK JASON B , BELL ADAM , SHI YANGGU , LAFLEUR DAVID
IPC分类号： A61K38/38 , C07K14/76 , C07K14/765 , C12N15/62
CPC分类号： C07K14/765 , A61K38/00 , C07K2319/31 , C07K2319/35 , C12N15/62
摘要： The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.
摘要翻译：本发明包括白蛋白融合蛋白。编码本发明的白蛋白融合蛋白的核酸分子也包括在本发明中，载体含有这些核酸，用这些核酸载体转化的宿主细胞，以及制备本发明的白蛋白融合蛋白并使用这些核酸的方法酸，载体和/或宿主细胞。另外，本发明包括包含白蛋白融合蛋白的药物组合物以及使用本发明的白蛋白融合蛋白来治疗，预防或改善疾病，病症或病症的方法。

8. 发明申请

WO2005018536A3 AGONIST ANTIBODIES THAT SPECIFICALLY BIND THE GLUCAGON LIKE PEPTIDE-1 RECEPTOR 审中-公开
公开(公告)号：WO2005018536A3
公开(公告)日：2005-03-03
申请号：PCT/US2004/015866
申请日：2004-05-20
申请人： HUMAN GENOME SCIENCES, INC. , ROSEN, Craig, A. , BELL, Adam
发明人： ROSEN, Craig, A. , BELL, Adam
IPC分类号： A61K39/395
摘要： The present invention relates to antibodies and related molecules that specifically bind to the glucagon like peptide-1 (GLP-1) receptor. Such antibodies have uses, for example, in the treatment of diabetes, obesity, hyperglycemia, neurodegenerative disorders, and heart disease. The invention also relates to nucleic acid molecules encoding anti-GLP-1 receptor antibodies, vectors and host cells containing these nucleic acids, and methods for producing the same. The present invention relates to methods and compositions for preventing, detecting, diagnosing, treating or ameliorating a disease or disorder including diabetes, obesity, hyperglycemia, neurodegenerative disorders, and heart disease, comprising administering to an animal, preferably a human, an effective amount of one or more antibodies or fragments or variants thereof, or related molecules, that specifically bind to the GLP-1 receptor.

9. 发明申请

WO02097038A2 CHEMOKINE BETA-1 FUSION PROTEINS 审中-公开
标题翻译： CHEMOKINE BETA-1融合蛋白
公开(公告)号：WO02097038A2
公开(公告)日：2002-12-05
申请号：PCT/US0216525
申请日：2002-05-24
申请人： HUMAN GENOME SCIENCES INC , BELL ADAM , RUBEN STEVEN M
发明人： BELL ADAM , RUBEN STEVEN M
IPC分类号： C07K14/52 , C12N
CPC分类号： C07K14/523 , C07K2319/00
摘要： The present invention relates to novel chemokine polypeptides and encoding nucleic acids. More specifically, therapeutic compositions and methods are provided using isolated nucleic acid molecules encoding a human chemokine beta-1 (Ck DOLLAR G(b)-1 or Ckb1) polypeptide (previously termed monocyte-colony inhibitory factor (M-CIF), MIP1-gamma, and Hemofiltrate CC chemokine-1 (HCC-1)), and Ckb1 polypeptides themselves, as are vectors, host cells and recombinant methods for producing the same. Also provided are methods of treating, preventing, ameliorating diseases using such compounds.
摘要翻译：本发明涉及新型趋化因子多肽和编码核酸。更具体地，使用分离的编码人趋化因子β-1（Ck DOLLAR G（b）-1或Ckb1）多肽（以前称为单核细胞集落抑制因子（M-CIF）），MIP1- γ和Hemofiltrate CC趋化因子-1（HCC-1））和Ckb1多肽本身，以及用于产生它们的载体，宿主细胞和重组方法。还提供了使用这些化合物治疗，预防和改善疾病的方法。

10. 发明申请

WO2012023046A3 PORTABLE SYSTEM FOR ANALYZING AND DETERMINING ELEMENTAL COMPOSITION OF ROCK SAMPLES 审中-公开
公开(公告)号：WO2012023046A3
公开(公告)日：2012-02-23
申请号：PCT/IB2011/002351
申请日：2011-08-19
申请人： FABER, Daniel , ODA, Susan , BELL, Adam , DUCELLIER, Thomas
发明人： FABER, Daniel , ODA, Susan , BELL, Adam , DUCELLIER, Thomas
IPC分类号： G01N23/05 , G21C17/10
摘要： A portable system for elemental analysis includes one or more neutron emitters, a chamber for containing a test sample, at least one gamma ray detector electrically connected to a data acquisition system, and software or firmware executing on the data acquisition system from a non-transitory physical medium, the software or firmware providing a first function for producing one or more gamma ray spectrums, a second function for applying correction factors to the one or more gamma ray spectrums, and a third function for analyzing the corrected gamma ray spectrum or spectrums to determine a deconvolved elemental composition of the test sample.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式